dc.creatorHeesom, Lesley
dc.creatorRehnberg, Lucas
dc.creatorNasim-Mohi, Myra
dc.creatorJackson, Alexander I.R.
dc.creatorCelinski, Michael
dc.creatorDushianthan, Ahilanadan
dc.creatorCook, Paul
dc.creatorRivinberg, William
dc.creatorSaeed, Kordo
dc.date.accessioned2020-09-30T21:39:31Z
dc.date.accessioned2022-09-23T18:16:23Z
dc.date.available2020-09-30T21:39:31Z
dc.date.available2022-09-23T18:16:23Z
dc.date.created2020-09-30T21:39:31Z
dc.identifier2213-7165
dc.identifierhttp://dx.doi.org/10.1016/j.jgar.2020.07.017
dc.identifierhttp://hdl.handle.net/20.500.12010/14055
dc.identifierhttp://dx.doi.org/10.1016/j.jgar.2020.07.017
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3498302
dc.description.abstractThe coronavirus-2019 (COVID-19) pandemic caused by the virus SARS-CoV-2 infection has imposed significant demand on all healthcare systems. Based on national and international guidance which were mostly anecdotal [1], COVID-19 patients admitted to our General Intensive Care Unit (GICU) were routinely commenced on antibiotics to cover possible secondary bacterial lower respiratory tract infection (LRTI). The antibiotics should have been reviewed after 48 h, however, it was challenging to stop early because of the many factors such as persistent hyperinflammatory status, ongoing/worsening lung infiltrates with the need for continued mechanical ventilation, and also partly because of the lack of reliable indicators of bacterial infection.
dc.languageeng
dc.publisherJournal of Global Antimicrobial Resistance
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightsAbierto (Texto Completo)
dc.sourcereponame:Expeditio Repositorio Institucional UJTL
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozano
dc.subjectCOVID-19
dc.subjectSARS-CoV-2
dc.subjectProcalcitonin
dc.subjectPCT
dc.subjectAntibiotic stewardship
dc.titleProcalcitonin as an antibiotic stewardship tool in COVID-19 patients in the intensive care unit


Este ítem pertenece a la siguiente institución